Effect of Herbal Extract Granules Combined With Probiotics on Irritable Bowel Syndrome With Diarrhea

Not Applicable

Completed

• Conditions: Irritable Bowel Syndrome
• Interventions: Dietary Supplement: Placebo herbal extract granule and probiotics; Dietary Supplement: Herbal extract granule and probiotics; Dietary Supplement: Placebo herbal extract granule and placebo probiotics; Dietary Supplement: Herbal extract granule and placebo probiotics

• Registration Number: NCT01342718
• Lead Sponsor: Kyunghee University Medical Center

Brief Summary

The aims of this study are to investigate the effect of famous herbal formula extract and probiotics on irritable bowel syndrome with diarrhea, and to determine whether these two experimental items affect intestinal permeability and the composition of intestinal microbiota.

Detailed Description

Irritable bowel syndrome (IBS), a common chronic gastrointestinal disorder characterized by abdominal pain and alteration of bowel habits in the absence of structural abnormality, has a prevalence of approximately 15% in western populations1,2. Patients with IBS can be classified by their predominant bowel habits: diarrhea-predominant IBS (D-IBS), constipation-predominant IBS, or IBS with alternating bowel movements3. Although smooth-muscle relaxants, bulking agents, and anti-diarrheal agents are commonly used as conventional IBS treatments, many IBS patients turn to alternative treatments because of the lack of therapeutic advantages of these treatments4. Therefore, the development of a new therapy is necessary for IBS patients.

Gwakhyangjeonggisan (GJS; Kkako-shoki-san in Kampo Medicine; Huoxiang-zhengqi-san in Traditional Chinese Medicine), which was recorded originally in the famous ancient herbal formula literature "Formularies of the Bureau of people's Welfare Pharmacies", consists of 13 common crude herbs. GJS contains the chemical ingredients naringin, hesperidin, thymol, honokiol and magnolol5. GJS has been shown to protect intestinal barrier function6, contract the colonic muscle7, and regulate infectious diarrhea8 in vivo. In traditional Korean medicine, this herbal formula has long been used for relieving abdominal pain, diarrhea, and vomiting as an over-the-counter or prescribed medicine9-11. However, there have been no clinical trials to investigate the efficacy of GJS in IBS.

Probiotics are defined as viable microorganisms, which confer potential health benefits on the host when taken in proper amounts12. They are easily available, do not require a prescription, and are administered extensively for the relief of abdominal symptoms13. According to a recent systematic review and meta-analysis study, probiotics caused a modest improvement in the overall IBS symptoms14. The rationale for using probiotics for IBS is based on the assumption that they modify the composition of the intestinal microflora15 and regulate intestinal permeability by modulating the epithelial tight junctions16. Duolac7S (DUO), a probiotic mixture, contains 7 bacterial species including Bifidobacterium, Lactobacillus, and Streptococcus. Each of these bacterial species is reportedly beneficial for IBS17. DUO has been approved by the Korean Food and Drug Administration for restoring the ecological balance of intestinal microflora and improving intestinal symptoms18. Although DUO has been widely used as an over-the-counter product for IBS-related symptoms, no clinical trials have investigated the efficacy of DUO on IBS.

Recently, several herbal formulas and probiotics have been simultaneously administered to IBS patients for relieving abdominal symptoms19. In addition to lack of clinical evidence for the use of GJS or DUO, the efficacy of their combined treatment for IBS has not been elucidated. Thus, there is a need to evaluate the safety and efficacy of administration of GJS, DUO, or a combination therapy as a frequently used treatment for IBS. In the current trial, we identified the safety and efficacy of GJS, DUO, or a combination therapy on D-IBS by evaluating IBS symptoms and quality of life. To investigate their mechanisms in humans, intestinal permeability and composition of intestinal microbiota were assessed.

Study Timeline

• Study Start: 2011-04
• Study First Submitted: 2011-04-25
• Study First Submitted QC: 2011-04-26
• Study First Posted: 2011-04-27
• Primary Completion: 2012-04
• Study Completion: 2012-04
• Status Verified: 2012-06
• Last Update Submitted: 2012-06-01
• Last Update Posted: 2012-06-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

1. Age of 18 - 75, with a elementary-school diploma or higher, must be literate
2. One who meet Rome Ⅲ IBS-D criteria
3. One who agree on not taking other therapies during experimental period
4. During the past 5 yrs, no history of organic lesion proven by colonoscopy
5. One who agree on consent form

Exclusion Criteria

1. Patients who have abdominal operation in the past(exception: appendectomy, caesarean section, tubal ligation, laparoscopic cholecystectomy, hysterectomy and abdominal wall hernia repair)
2. No history of non-functional bowel disease(cholangitis, pancreatitis, enteritis, ulcer, bleeding, cancer, etc.)
3. Before participation clinical trial, one who took over-the-count medication affecting GI motility
4. One who takes antibiotics during run-in period (2 wks)
5. One who takes probiotics within 2 wks before experiment
6. Pregnant woman
7. One who disagree on the consent form

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
GJS-P/Duolac7S	Placebo herbal extract granule and probiotics	GJS-P: Placebo herbal extract granule/Duolac7S: Real probiotics
GJS/Duolac7S	Herbal extract granule and probiotics	GJS: Real herbal extract granule/Duolac7S: Real probiotics
GJS-P/Duolac7S-P	Placebo herbal extract granule and placebo probiotics	GJS-P: Placebo herbal extract granule/Duolac7S-P: Placebo probiotics
GJS/Duolac7S-P	Herbal extract granule and placebo probiotics	GJS: Real herbal extract granule/Duolac7S-P: Placebo probiotics

Primary Outcome Measures

Name	Time	Method
Adequate relief (AR) of IBS pain & discomfort	Weekly (during run-period [2 wks], administarion period [8 wks] and follow-up period [2 wks])	As the participants answer the question "in the past seven days have you had adequate relief of your irritable bowel syndrome pain and discomfort?" in the form of "Yes" or "No", the effect can be assessed.
Proportion of responders	Once in each period (run-period [2 wks], administarion period [8 wks] and follow-up period [2 wks])	The proportion of responders who answer "Yes" to more than half of AR questions in each period (\>50%)

Secondary Outcome Measures

Name	Time	Method
Daily assessment of bowel function scores	Daily (during run-period [2 wks], administarion period [8 wks] and follow-up period [2 wks])	1. The patients should write diaries of stool's frequency, consistency and ease of passage; 2. Frequency (number of defecation in a day); 3. Consistency (judged by Bristol scale); 4. Ease of passage
Daily assessment of severity of individual symptoms related to defecation	Daily (during run-period [2 wks], administarion period [8 wks] and follow-up period [2 wks])	Abdominal pain, abdominal discomfort, bloating, flatulence, urgency, mucus in stool and overall symptom would be evaluated through visual analog scale (100mm)
Changes on population of intestinal microbes	Two times in administration period (0 and 8 wks)	1. To investigate the changes of intestinal microbes before and after experiment, feces should be collected.; 2. The feces will be analyzed by the method of DGGE (denaturing gradient gel electrophoresis - PCR of DNA).
Intestinal permeability test	Two times in administration period (0 and 8 wks)	In order to evaluate intesinal permeability, the urine should be collected after orally administration of lactulose and mannitol.

Trial Locations

Locations (1)

Kyung Hee University Hospital at Gangdong; 🇰🇷 Seoul, Gangdong-gu, Korea, Republic of